Researchers identify process vital to placenta growth in early pregnancy

Washington D.C. [USA], Feb 26 (ANI): Normal rate of placenta growth is essential to decline the chances of pregnancy complications such as miscarriages, preeclampsia and foetal growth restriction. In a recent study, researchers have discovered the process that contributes to placental implantation during early pregnancy as well as cancer progression and spread.
The study, led by the University of South Florida Health (USF Health) Morsani College of Medicine researchers, discovered how a very large human non-protein coding gene regulates epithelial-to-mesenchymal transition (EMT) the process that is vital to placenta growth in early pregnancy. The study was published in the journal Scientific Reports.
The USF Health researchers used a powerful genome editing technology called CRISPR (shorthand for "CRISPR-dCas9) to activate all of the chromosome 19 microRNA cluster (known as C19MC), so they could study the gene's function in early pregnancy. C19MC -- one of the largest microRNA gene clusters in the human genome -- is normally turned off and becomes expressed only in the placenta, embryonic stem cells and certain cancers.
In their cell model study, a Nature research journal, the USF Health team showed that robustly activating C19MC inhibited EMT.
But when cells from which the placenta arises (trophoblasts) were exposed to hypoxia - a lack of oxygen like that occurring in early placental development -- C19MC expression was significantly reduced, the researchers found. This loss of C19MC function then freed the trophoblasts to differentiate from stem-like epithelial cells into mesenchymal cells that can migrate and invade much like metastatic tumours.
"We were the first to use CRISPR to efficiently activate the entire gene, not just a few regions of this huge gene, in human cell lines," said the paper's senior author Hana Totary-Jain, PhD, an associate professor in the Department of Molecular Pharmacology and Physiology, USF Health Morsani College of Medicine. "Our study indicates C19MC plays a key role in regulating many genes important in early implantation and placental development and function. The regulation of these genes is critical for proper fetal growth."
Dr Totary-Jain and others in her department collaborated with colleagues in the medical college's Department of Obstetrics and Gynecology on the project.
The USF Health study offers new insight into how trophoblasts interact with the maternal uterine environment to become more invasive or less invasive in the formation of the placenta, said co-author Umit Kayisli, PhD, a USF Health professor of obstetrics and gynaecology. "More research on microRNA expression and how it inhibits the epithelial-to-mesenchymal transition may help us better understand and control preeclampsia and fetal growth restriction, which account for 5-to-10 per cent of all pregnancy complications and premature births."
EMT happens early in the formation of the placenta, an organ that attaches to the lining of the uterus during pregnancy and supplies oxygen and nutrients from mother to the growing fetus. During the first trimester, fetal trophoblasts penetrate the maternal uterine lining and modify its blood vessels. This remodelling of the mother's spiral arteries allows oxygenated blood to flow from the mother to fetus.
However, the trophoblast invasion prompted by EMT is a tightly coordinated balancing act. If the invasion is too shallow to adequately remodel the maternal blood vessels, preeclampsia and fetal growth restriction can occur. Invasion that progresses too deeply -- beyond normal anchoring of the placenta to the uterine wall - leads to placenta accreta, a rare condition that can cause dangerous bleeding and often require pregnancy termination.
"You need the EMT process, but at some point, it needs to stop to prevent adverse pregnancy outcomes," Dr. Totary-Jain said. "You really need a balance between not enough invasion and too much invasion, and C19MC is important in maintaining that balance." (ANI)